Innate Pharma S.A.

Ladies and gentlemen, thank you for joining us and welcome to the Innate Farmer third quarter 2025 business update and financial results. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please raise your hand. If you have dialled into today's call, please press star nine to raise your hand and star six to unmute. I will now hand the conference over to Stephanie Cornyn, Vice President, Investor Relations, Communication and Commercial Strategy at N8 Pharma. Please go ahead.

Good morning and good afternoon everyone. Thank you for joining us for INET Pharma Q3 2025 Business Update and Financial Results Conference Call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I'd like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. To begin, I briefly cover today's agenda. Our CEO, Jonathan Dickinson, will discuss our strategic priorities and pass forward. Then our CMO, Sonia Quarantino, will present clinical pipeline updates on IPH4502, Monalizumab, and Lacutamab. Afterward, I will present the commercial opportunity for Lacutamab before turning back to Jonathan with closing remarks and will open for the call for Q&A. With that, I'll now hand it over to Jonathan.

Thank you, Stephanie. Good morning to those joining from the U.S. and good afternoon to our European audience. Turning to slide five, I would like to start with the strong momentum around LakutaMap, supported by meaningful regulatory progress and new commercial opportunity insights. A few days ago, we received FDA clearance to initiate the TELEMAT3 phase 3 trial in cutaneous T-cell lymphoma. This is a major milestone for the program, positioning leucutumab to advance towards potential accelerated approval in cesarean syndrome, supported by robust phase 2 data. We expect the study to initiate in the first half of 2026, with filing anticipated following achievement of key enrollment milestones. Our CMO, Sonia Quarantino, will provide additional color on the phase three trial and the regulatory path. In parallel, we hosted a well-attended Lekutamab KOL event in October, featuring leading experts in ctcl the discussions highlighted the continued unmet medical need for new effective and well-tolerated therapies in this space and reinforced lakutamab's unique positioning during the event we also presented new real-world claims data, underscoring the commercial opportunity in both CTCL, which we believe further strengthens the value proposition for this program. Stephanie Cornyn, our Vice President of Investor Relations and Commercial Strategy, will review the real-world evidence-based commercial opportunities for Lacutamab towards the end of our call today. Moving to slide six, as you know, innate pharma's core strength lies in applying our deep scientific expertise to advance life enhancing cancer therapies. Through our years of pioneering work in antibody engineering, we have built a differentiated high value clinical pipeline supported by compelling data. positioning us to deliver treatments with truly transformative potential for patients and for all our stakeholders. Moving to slide seven, as we look ahead, our path forward is clear and focused. As you remember, at our half year results, we announced the strategic decision to focus our investment on what we believe are our highest value clinical assets. including IPH4502, lacutamab, and monolizumab to maximize impact and value creation. In parallel, we're advancing our next generation of ADC programs through research, building the foundation for future innovation. Finally, we are streamlining the organization to ensure we remain fit for purpose and aligned with our strategic objectives. I'll now hand over to Sonia, who will take us through the clinical pipeline progress. Sonia.